Background: Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine.
Objective and results: Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle.
Conclusion: Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.
Keywords: Relapsing multiple sclerosis; adverse event; anti-glomerular basement membrane antibodies; autoimmune hepatitis; cladribine tablets; secondary autoimmunity; thrombocytopenia.